These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31037433)

  • 1. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
    Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
    Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
    Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
    Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
    Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.
    Wu YY; Dai L; Yang YB; Yan WP; Cheng H; Fan MY; Gao YM; Chen KN
    Ann Surg Oncol; 2024 Aug; 31(8):5047-5054. PubMed ID: 38172446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy.
    Deng W; Xu C; Liu A; van Rossum PSN; Deng W; Liao Z; Koong AC; Mohan R; Lin SH
    Radiother Oncol; 2019 Apr; 133():9-15. PubMed ID: 30935587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.
    Okumura H; Uchikado Y; Omoto I; Kita Y; Sasaki K; Arigami T; Uenosono Y; Matsushita D; Hiraki Y; Owaki T; Ishigami S; Natsugoe S
    Ann Surg Oncol; 2014 Sep; 21(9):2845-9. PubMed ID: 24728820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
    Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
    Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.
    Zhou XL; Zhu WG; Zhu ZJ; Wang WW; Deng X; Tao WJ; Ji FZ; Tong YS
    Oncologist; 2019 Aug; 24(8):e677-e686. PubMed ID: 31040254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
    Davuluri R; Jiang W; Fang P; Xu C; Komaki R; Gomez DR; Welsh J; Cox JD; Crane CH; Hsu CC; Lin SH
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):128-135. PubMed ID: 28816138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.